Advanced Science,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 16, 2024
Abstract
Ischemia‐reperfusion
injury
(IRI)
is
the
leading
cause
of
hepatic
graft
dysfunction,
resulting
from
hepatocyte
damage.
Nevertheless,
given
few
specialized
therapeutics
available
in
IRI,
additional
mechanistic
insights
into
damage
are
required.
Here,
protein
solute
carrier
family
39
member
14
(SLC39A14)
identified
as
a
pro‐ferroptosis
target
hepatocytes
human
liver
allografts
through
single‐cell
RNA
sequencing
analysis.
SLC39A14
knockdown
significantly
mitigated
IRI
by
preventing
ferroptosis
vivo
and
vitro.
Mechanistically,
inhibition
suppressed
non‐transferrin‐bound
iron
(NTBI)
uptake
hepatocytes,
thereby
reducing
overload
cell
ferroptosis.
Moreover,
bone
marrow‐derived
mesenchymal
stem
cells
(hBMSCs)
found
to
exhibit
notable
therapeutic
effect
on
downregulating
expression.
Exosomes
derived
hBMSCs
delivered
abundant
miR‐16‐5p
which
post‐transcriptionally
expression
reduced
induced
IRI.
In
conclusion,
triggers
mediating
NTBI
inducing
hBMSC‐based
therapy
promising
reverse
this
progression
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(50), P. 33907 - 33921
Published: Dec. 3, 2024
Acute
liver
failure
(ALF)
is
a
serious
global
disease
characterized
by
rapid
onset
and
high
mortality.
Currently,
the
clinical
treatment
of
ALF
faces
considerable
hurdles
due
to
limited
medication
options
scarcity
transplants.
Despite
biomacromolecules
such
as
hepatocyte
growth
factor
(HGF)
glutathione
(GSH)
having
been
applied
for
symptom
relief
in
clinic,
they
still
face
substantial
challenges
including
poor
stability,
difficulty
acting
on
intracellular
targets,
inadequate
therapeutic
outcome.
In
this
work,
taking
advantage
innate
targeting
regenerative
capabilities
mesenchymal
stem
cells
(MSCs),
we
harnessed
MSC-derived
exosomes
natural
bioactive
carriers
simultaneous
delivery
HGF
GSH,
forming
fully
nanodrug
termed
HG@Exo.
Impressively,
HG@Exo
demonstrated
potent
effects
against
both
carbon
tetrachloride
(CCl
As
naturally
secreted
vesicles
by
cells,
extracellular
(EVs)
play
essential
roles
in
modulating
cell–cell
communication
and
have
significant
potential
tissue
regeneration,
immune
regulation,
drug
delivery.
However,
the
low
yield
uncontrollable
heterogeneity
of
EVs
been
obstacles
to
their
widespread
translation
into
clinical
practice.
Recently,
it
has
discovered
that
artificial
nanovesicles
(NVs)
produced
cell
processing
can
inherit
components
functions
parent
cells
possess
similar
structures
EVs,
with
significantly
higher
yields
more
flexible
functionalization,
making
them
a
powerful
complement
natural
EVs.
This
review
focuses
on
recent
advances
research
NVs
as
replacements
for
We
provide
an
overview
comparing
summarize
top-down
preparation
strategies
NVs.
The
applications
prepared
from
stem
differentiated
engineered
are
presented,
well
latest
NV
engineering.
Finally,
main
challenges
discussed.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Nov. 11, 2024
Immune
checkpoint
inhibitors
(ICIs)
have
revolutionized
cancer
treatment,
demonstrating
unprecedented
efficacy
against
advanced
cancers.
However,
their
clinical
applications
are
significantly
hampered
by
low
overall
response
rates.
Dual
blockade
of
two
immune
checkpoints
represents
a
promising
strategy
to
enhance
immunotherapeutic
efficacy.
In
this
study,
we
developed
hybrid
cell
membrane
nanovesicles
adorned
with
PD-1
and
SIRPα
receptors
for
combination
immunotherapy
in
melanoma.
Our
(PD-1/SIRPα
NVs)
demonstrated
high
specificity
PD-L1
CD47
ligands,
facilitating
the
phagocytosis
melanoma
cells
macrophages.
mouse
model,
PD-1/SIRPα
NVs
suppressed
77%
tumor
growth
elicited
robust
antitumor
immunotherapy.
conclusion,
our
findings
highlight
potential
as
novel
effective
ICIs
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 12793 - 12815
Published: Nov. 1, 2024
Plant-derived
exosome-like
nanovesicles
(PELNs)
from
edible
plants,
isolated
by
ultracentrifugation,
size
exclusion
chromatography
or
other
methods,
were
proved
to
contain
a
variety
of
biologically
active
and
therapeutically
specific
components.
Recently,
investigations
in
the
field
PELN-based
biomedicine
have
been
conducted,
which
positioned
those
as
promising
tools
for
prevention
treatment
several
diseases,
with
their
natural
origin
potentially
offering
superior
biocompatibility
bioavailability.
However,
inadequate
targeting
limited
therapeutic
effects
constrain
utility
clinical
translation
PELNs.
Thus,
strategies
aiming
at
bridging
gap
engineering
PELNs
great
interest.
Those
approaches
include
membrane
hybridization,
physical
chemical
surface
functionalization
encapsulation
payloads.
Herein,
we
provide
comprehensive
overview
biogenesis
composition,
isolation
purification
methods
characterization
PELNs,
well
functions.
Current
knowledge
on
construction
biomedical
application
engineered
reviewed.
Additionally,
future
directions
perspectives
this
discussed
order
further
enrich
expand
prospects
Advanced Science,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 16, 2024
Abstract
Ischemia‐reperfusion
injury
(IRI)
is
the
leading
cause
of
hepatic
graft
dysfunction,
resulting
from
hepatocyte
damage.
Nevertheless,
given
few
specialized
therapeutics
available
in
IRI,
additional
mechanistic
insights
into
damage
are
required.
Here,
protein
solute
carrier
family
39
member
14
(SLC39A14)
identified
as
a
pro‐ferroptosis
target
hepatocytes
human
liver
allografts
through
single‐cell
RNA
sequencing
analysis.
SLC39A14
knockdown
significantly
mitigated
IRI
by
preventing
ferroptosis
vivo
and
vitro.
Mechanistically,
inhibition
suppressed
non‐transferrin‐bound
iron
(NTBI)
uptake
hepatocytes,
thereby
reducing
overload
cell
ferroptosis.
Moreover,
bone
marrow‐derived
mesenchymal
stem
cells
(hBMSCs)
found
to
exhibit
notable
therapeutic
effect
on
downregulating
expression.
Exosomes
derived
hBMSCs
delivered
abundant
miR‐16‐5p
which
post‐transcriptionally
expression
reduced
induced
IRI.
In
conclusion,
triggers
mediating
NTBI
inducing
hBMSC‐based
therapy
promising
reverse
this
progression
